EP0325428A2 - 6' Karbaminsäure-Ester von Zearalanol und deren Derivate - Google Patents

6' Karbaminsäure-Ester von Zearalanol und deren Derivate Download PDF

Info

Publication number
EP0325428A2
EP0325428A2 EP89300445A EP89300445A EP0325428A2 EP 0325428 A2 EP0325428 A2 EP 0325428A2 EP 89300445 A EP89300445 A EP 89300445A EP 89300445 A EP89300445 A EP 89300445A EP 0325428 A2 EP0325428 A2 EP 0325428A2
Authority
EP
European Patent Office
Prior art keywords
compound
composition
membered
ruminant
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP89300445A
Other languages
English (en)
French (fr)
Other versions
EP0325428A3 (de
Inventor
Edward B. Hodge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Veterinary Inc
Original Assignee
Pitman Moore Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pitman Moore Inc filed Critical Pitman Moore Inc
Publication of EP0325428A2 publication Critical patent/EP0325428A2/de
Publication of EP0325428A3 publication Critical patent/EP0325428A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates generally to Resorcylic Acid Lactone (RAL) derivatives and particularly to 6′ carbamate esters of zearalanol and its derivatives which are useful for promoting growth in ruminants.
  • RAL Resorcylic Acid Lactone
  • Zearalenone and its derivatives are the basic Resorcylic Acid Lactone (RAL) compounds used as the starting materials for the compounds of the present invention.
  • Zearalenone may be prepared by culturing the zearalenone producing strain of Gibberella zeae as taught in U.S. Patent No. 3,196,019, incorporated herein by reference. Zearalenone and its ring-opened and other derivatives have been reviewed in the literature. Shipchandler, Heterocycles , 3(6):471-520 (1975) and Hidy et al "Zearalone and Some Derivatives: Production and Biological Activities", Adv. Appl. Microbiol. , 22:59-82 (1977).
  • Zearalone has been chemically modified to form numerous derivatives.
  • the compounds of the present invention have the structure: wherein R1 and R2, which may be the same or different, are H, X, or COX, where X is an alkyl group having from 1-6 carbon atoms; and R is NH-Y, where Y is an alkyl group having from 1-6 carbon atoms or a five-membered or six-membered ring; N(C n H 2n+1 )2, where n is an integer from 1 to 6; or a five-membered or six-membered heterocyclic ring having one N heteroatom and up to one other heteroatom selected from the group consisting on N, S, and O heteroatoms.
  • R1 and R2 are H, CH3, or COCH3; and R is C6H12N (cyclohexylamino), N(CH3)2, N(C2H5)2, C5H10N (piperidino), C4H8ON (morpholino), C4H8SN (thiamorpholino) or C4H8N (pyrrolidino).
  • 6′ carbamate esters of zearalanol and its derivatives are synthesized and used to promote growth in ruminants.
  • the compounds have the following structural formula (I) wherein R1 and R2, which may be the same or different, are H, X, or COX, where X is an alkyl group having from 1-6 carbon atoms; and R is NH-Y, where Y is an alkyl group having from 1-6 carbon atoms or a five-membered or six-membered ring; N(C n H 2n+1 )2, where n is an integer from 1 to 6; or a five-membered or six-membered heterocyclic ring having one N heteroatom and up to one other heteroatom selected from the group consisting on N, S, and O heteroatoms.
  • R1 and R2 are H, CH3, or COCH3; and R is C6H12N (cyclohexylamino), N(CH3)2, N(C2H5)2, C5H10N (piperidino), C4H8ON (morpholino), C4H8SN (thiamorpholino), or C4H8N (pyrrolidino).
  • the compounds are formed by reacting zearalanol and its derivatives directly with carbamyl chlorides or by reacting carbonate derivatives of zearalanol directly with the appropriate amine; typically an amine having the formula NH2-Y, where Y is an alkyl group having from 1-6 carbon atoms or a five-membered or six-membered ring, NH(C n H 2n+1 )2, where n is an integer from 1 to 6, or five-membered or six-membered heterocyclic compounds having one N heteroatom and up to one other heteroatom selected from the group consisting on N, S, and O heteroatoms.
  • NH2-Y where Y is an alkyl group having from 1-6 carbon atoms or a five-membered or six-membered ring, NH(C n H 2n+1 )2, where n is an integer from 1 to 6, or five-membered or six-membered heterocyclic compounds having one N heteroatom and up to one other heteroatom selected from
  • These compounds include but are not limited to methylamine, ethylamine, cyclohexamine, piperidine, morpholine, thiamorpholine, and pyrrolidine.
  • Methods for preparing carbonate derivatives of zearalanol useful in the present invention are disclosed in copending U.S. Patent Application Serial No. 067,532, incorporated herein by reference.
  • the invention provides a process for the preparation of compounds of formula (1) said process comprising one of the following steps:
  • the amount of compound of the present invention administered may vary depending upon the particular type, maturity, and the size of the ruminant.
  • the compounds according to the present invention are administered to the ruminant in dosages of from 0.01-0.50 mg/kg of body weight, preferably from 0.1-0.3 mg/kg of body weight.
  • the compounds of the present invention can be administered as the compound or as a pharmaceutically acceptable salt of the compound, alone, in combination, or in combination with pharmaceutically acceptable carriers, diluents, and vehicles.
  • the carrier can be an antibiotic, other growth promoting agent, an inert carrier, and the like.
  • the compounds of the present invention are mixed with a pharmaceutically acceptable carrier to form a composition which allows for easy dosage preparation and administration.
  • the compounds of the present invention can be administered to ruminants by any suitable method including orally, by injection, using an implant, and the like.
  • Oral administration includes administering the compounds of the present invention in tablets, suspensions, implants, solutions, emulsions, capsules, powders, syrups, water compositions, boluses, feed compositions, and the like. Injections and implants are preferred because they permit precise control of the timing and dosage levels used for administration, with implants being most preferred.
  • the compounds of the present invention are preferably administered parenterally. Such administration may be by intravenous or intramuscular injection, intraperitoneal injection, or subcutaneous implant.
  • the compounds according to the present invention can be administered to the ruminant in the form of a slow-release subcutaneous implant which is inserted beneath the skin of the ruminant, preferably in the ear for large animals.
  • the implant can take the form of a pellet which slowly dissolves after being implanted in the ruminant or a biocompatible and compound compatible delivery module well known to those skilled in the art.
  • Such well known dosage forms are designed such that the active ingredients are slowly released over a period of several days to several weeks.
  • the implant is designed to deliver from about 0.15-8.5 ⁇ g/kg of body weight/day, preferably from about 1.5-5.0 ⁇ g/kg of body weight/day.
  • the compounds of the present invention can be administered to the ruminants with any biocompatible and compound compatible carrier such as various vehicles, adjuvants, additives, and diluents to achieve a composition usable as a dosage form.
  • the compounds of the present invention are added to the carrier in amounts sufficient to supply from about 0.01-0.5 mg/kg of body weight to the ruminant when injected.
  • the compounds of the present invention are added to an oil vehicle in amounts sufficient to supply from about 0.1-0.3 mg/kg of body weight.
  • Aqueous vehicles such as water having no nonvolatile pyrogens, sterile water, and bacteriostatic water are also suitable to form injectable compound compositions.
  • aqueous vehicles can be used. These include isotonic injection compositions that can be sterilized such as Ringer's, dextrose, dextrose and sodium chloride, and lactated Ringer's. Addition of water-miscible solvents, such as methanol, ethanol, or propylene glycol generally increases solubility of the compounds in these vehicles.
  • Nonaqueous vehicles such as cottonseed oil, sesame oil, or peanut oil and esters such as isopropyl myristate may also be used as solvent systems for compound compositions. Additionally various additives which enhance the stability, sterility, and isotonicity of the composition including antimicrobial preservatives, antioxidants, chelating agents, and buffers can be added. Any vehicle, diluent, or additive used would, however, have to be compatible with the compounds of the present invention.
  • the compounds according to the present invention can be administered orally to the ruminant.
  • the compounds of the present invention can be blended with ordinary feed compositions in amounts sufficient to promote growth.
  • a ruminant feed composition may be prepared containing the usual nutritionally-balanced feed containing quantities of carbohydrates, proteins, vitamins and minerals, together with the compounds in accordance with the present invention.
  • ruminant feed compositions Some of the usual dietary elements included in ruminant feed compositions are grains, such as ground grain and grain byproducts, animal protein substances, such as those found in fish meal and meat scraps, vegetable proteins, like soybean oil meal or peanut oil meal; vitamins and vitamin-containing materials, e.g., vitamin A and D mixtures, riboflavin supplements and other vitamin B complex members; and bone meal and limestone to provide minerals.
  • a type of conventional feed material for use with cattle includes alfalfa hay and ground corncobs together with supplementary vitamins and vitamin-containing substances if desired.
  • the compounds according to the present invention are admixed with the feed in amounts sufficient to supply from about 0.01-0.50 mg/kg body weight, typically 0.4-20 grams/ton of feed, to the ruminant.
  • the compounds of the present invention are useful as growth promotants in ruminants.
  • the compounds can be used in post-menopausal replacement therapy.
  • carbamate derivatives of the present invention are cleaved in vivo to form the corresponding alcohol.
  • carbamates of zearalanol are hydrolyzed in vivo to form zearalanol.
  • the parent compound, zearalanol in the example effects the desired growth promotion or other effect.
  • a significant advantage is achieved by administering the derivative instead of parent compound; the derivative is not cleared by the body as fast as is the parent compound, thus allowing the growth promoting effect to be extended over a longer period. This increases the amount of growth promotion produced by a given amount of compound, reduces the amount of compound that must be administered to achieve the desired growth promotion, and decreases the number of dosages that must be administered in a given time.
  • the uterotropic activity screening test was conducted in young adult female mice (CFl strain) weighing 19-24 g each, purchased from Engle's Laboratory Animals, farmersburg, Indiana. The test mice were ovariectomized and held for two weeks to allow for depletion of natural estrogens.
  • mice were sacrificed, body weights were made and recorded, the uterus of each mouse removed, weighed and recorded. Average body and uterine weights were calculated. For comparison, the percent uterine weight to body weight was determined.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
EP19890300445 1988-01-19 1989-01-18 6' Karbaminsäure-Ester von Zearalanol und deren Derivate Withdrawn EP0325428A3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US145057 1988-01-19
US07/145,057 US4902711A (en) 1988-01-19 1988-01-19 6' Carbamate esters of zearalanol and its derivatives

Publications (2)

Publication Number Publication Date
EP0325428A2 true EP0325428A2 (de) 1989-07-26
EP0325428A3 EP0325428A3 (de) 1990-09-05

Family

ID=22511407

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890300445 Withdrawn EP0325428A3 (de) 1988-01-19 1989-01-18 6' Karbaminsäure-Ester von Zearalanol und deren Derivate

Country Status (10)

Country Link
US (1) US4902711A (de)
EP (1) EP0325428A3 (de)
JP (1) JPH01216987A (de)
KR (1) KR0128342B1 (de)
AU (1) AU613694B2 (de)
CA (1) CA1314045C (de)
HU (1) HU203337B (de)
IL (1) IL88990A (de)
NZ (1) NZ227657A (de)
PL (1) PL277241A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021213A1 (en) 2006-08-11 2008-02-21 Nicolas Winssinger Macrocyclic compounds useful as inhibitors of kinases and hsp90
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409392A (en) * 1981-09-03 1983-10-11 International Minerals & Chemical Corp. 6' Esters of zearalanol
US4751239A (en) * 1987-06-29 1988-06-14 International Minerals & Chemical Corp. 6' Carbonate esters of zearalanol and its derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196019A (en) * 1964-04-06 1965-07-20 Purdue Research Foundation Anabolic and estrogenic compound and process of making
US3239348A (en) * 1965-02-15 1966-03-08 Commercial Solvents Corp Estrogenic compounds and animal growth promoters
US3239354A (en) * 1965-02-15 1966-03-08 Commercial Solvents Corp Estrogenic compounds and animal growth promoters
NL131475C (de) * 1965-02-15
US3239346A (en) * 1965-02-15 1966-03-08 Commercial Solvents Corp Estrogenic compounds and animal growth promoters
US3239345A (en) * 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US3860616A (en) * 1969-05-01 1975-01-14 Merck & Co Inc Synthesis of d,1-zearalanol
US4088658A (en) * 1976-11-04 1978-05-09 Imc Chemical Group, Inc. Synthesis of dideoxyzearalane and related compounds
US4443470A (en) * 1981-09-03 1984-04-17 International Minerals & Chemical Corp. Method of promoting growth and enhancing feed efficiency in meat producing animals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409392A (en) * 1981-09-03 1983-10-11 International Minerals & Chemical Corp. 6' Esters of zearalanol
US4751239A (en) * 1987-06-29 1988-06-14 International Minerals & Chemical Corp. 6' Carbonate esters of zearalanol and its derivatives

Also Published As

Publication number Publication date
PL277241A1 (en) 1989-11-27
HU203337B (en) 1991-07-29
NZ227657A (en) 1990-11-27
AU613694B2 (en) 1991-08-08
AU2857789A (en) 1989-07-20
IL88990A (en) 1994-07-31
KR890011870A (ko) 1989-08-23
IL88990A0 (en) 1989-08-15
HUT49339A (en) 1989-09-28
US4902711A (en) 1990-02-20
JPH01216987A (ja) 1989-08-30
CA1314045C (en) 1993-03-02
KR0128342B1 (ko) 1998-04-03
EP0325428A3 (de) 1990-09-05

Similar Documents

Publication Publication Date Title
US4287201A (en) Anovulatory method and chicken feed compositions
US4902711A (en) 6' Carbamate esters of zearalanol and its derivatives
US4751239A (en) 6' Carbonate esters of zearalanol and its derivatives
US3373038A (en) Estrogenic compounds and animal growth promoters
US4239772A (en) Allyl and propyl zearalenone derivatives and their use as growth promoting agents
US3239346A (en) Estrogenic compounds and animal growth promoters
US3948911A (en) Substituted quinoxaline-2-carboxamide 1,4-dioxides
US3764614A (en) F.e.s. derivatives
US3896137A (en) 8-alkyl and alkenyl-10-hydroxy-5h(1)benzopyranopyridine derivatives and uses thereof
US5210097A (en) Xanthocillin x monomethyl ether derivative and antitumor agent containing the same
AU613649B2 (en) Compositions and methods for promoting growth of animals
US4015014A (en) Method for the use of aryl azines as anthelmintics
US3706769A (en) Thiophene-1,1-dioxides
US3449360A (en) Dithioacid esters
US3960835A (en) Zearaline glycoside compounds
US2929713A (en) Preparation of coumestrol esters and use thereof
US5312833A (en) Method of inhibiting tumor growth using xanthocillin X dimethylether
US3759903A (en) Thiazolinyl and thiazinyl derivatives of indazoles
US4267191A (en) Process for enhancing growth promotion in animals
US4007184A (en) Substituted alkyl esters of quinoxaline-di-N-oxide-2-carboxylic acid
US3178340A (en) Animal quieting composition and method of using same
US3915966A (en) Morpholino zearalins
EP0104836B1 (de) Eine ein (1-Oxo-2-pyridyl)disulfid enthaltende Futterzusammensetzung
US3907994A (en) Substituted alkyl esters quinoxaline-di-N-oxide-2-carboxylic acid as growth promoting agents
US3818007A (en) Hydroxyalkyl esters of quinoxaline-di-n-oxide-2-carboxylic acid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19901210

17Q First examination report despatched

Effective date: 19930408

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PITMAN-MOORE, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940222